Education
About Us
Working with TipRanks
Follow Us
Elanco Animal Health (ELAN)
:ELAN
ELAN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.02 - $19.70
Previous CloseN/A
Volume2.53M
Average Volume (3M)8.79M
Market Cap
$9.74B
Enterprise Value$10.81B
Total Cash (Recent Filing)$539.00M
Total Debt (Recent Filing)$4.21B
Price to Earnings (P/E)22.5
Beta1.38
Next Earnings
Nov 11, 2025EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding496,813,700
10 Day Avg. Volume5,787,630
30 Day Avg. Volume8,793,267
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue2.41
Enterprise Value/Gross Profit5.61
Enterprise Value/Ebitda7.08
Forecast
1Y Price Target
$19.19Price Target Upside-2.14% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial PerformanceElanco reported upside 2Q results, with sales, EBITDA, and EPS all ahead of expectations.
Market Share GrowthCredelio Quattro’s U.S. market share is expected to grow significantly, contributing over 150 basis points to revenue growth.
Product InnovationSeveral new products are contributing to a projected 400-500 basis points of revenue growth, with momentum expected to continue.
Bears Say
Competitive LandscapeThe implied 4Q guidance appears conservative to account for potential changes to the competitive landscape, at this juncture, but does imply a deceleration in revenue growth.
Market CompetitionThe backdrop could become more challenging due to potential new entrants in the market.
Elanco Animal Health News
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $8.02 and its highest was $19.70 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is $9.74B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Nov 11, 2025 which is in 45 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on Aug 07, 2025. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.199 by $0.061.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Overvalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.13.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 496,813,700 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $0.26 in its last earnings report, beating expectations of $0.199. Following the earnings report the stock price went up 18.136%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in ELAN
Elanco Animal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.19 (-2.14% Downside)
$19.19 (-2.14% Downside)
Blogger Sentiment
Neutral
ELAN Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 5.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 28.4%
Last 30 Days ▲ 28.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.82%
12-Months-Change
Fundamentals
Return on Equity
6.83%
Trailing 12-Months
Asset Growth
-0.16%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
ELAN Company Deck
ELAN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with significant growth in organic revenue and innovation, supported by a robust Farm Animal segment and improved leverage ratios. However, the impact of tariffs and increased operating expenses, along with a decline in gross margin, presented challenges. The positive aspects of the call, including record growth and innovation success, outweigh the lowlights.View all ELAN earnings summariesELAN Stock 12 Month Forecast
Average Price Target
$19.19
▼(-2.14% Downside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Teva Pharmaceutical
―
Zoetis
―
Phibro Animal Health
―
Ownership Overview
0.95% Insiders
49.64% Mutual Funds
1.00% Other Institutional Investors
34.06% Public Companies and
Individual Investors